CGNSF.US Cognetivity Neurosciences Ltd

Healthcare Health Care Technology USA Stocks
0.0001 USD
Close of Nov 13, 2026
0.0001 0.0001
Market cap
USD 8.96K
P/E
-
P/B
189.01x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Oct 2023.

Is CGNSF.US undervalued?

Graham number

The Graham number of Cognetivity Neurosciences Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cognetivity Neurosciences Ltd fundamental analysis

No fundamental analysis for Cognetivity Neurosciences Ltd yet.

Cognetivity Neurosciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cognetivity Neurosciences Ltd

Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Va…

Full company profile